New drug combo trial offers hope for Tough-to-Treat cancers
NCT ID NCT07131202
Summary
This study is testing a new drug called FL115 when given together with an existing immunotherapy drug (Sintilimab) for people with advanced solid tumors. The main goals are to find a safe dose and see if the combination shows early signs of helping to control the cancer. About 130 participants will receive the treatment until their cancer grows, they have bad side effects, or they choose to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.